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Abstract
Background: Chronic hepatitis B virus (HBV) infection is a known major etiological factor for hepatocellular
carcinoma (HCC) development. Alpha-fetoprotein (AFP) is widely used to detect primary HCC, whereas its sensitivity
and specificity are not satisfying. Recently, circulating microRNAs (miRNAs) have been reported to be promising
biomarkers for diagnosing and monitoring cancers. This study was conducted to detect the application of serum
miR-150 in the diagnosis and prognosis of HBV-related HCC.
Methods: The expression of miR-150 was evaluated using a real-time quantitative RT-PCR in 350 serum samples
(120 samples from controls, 110 from chronic hepatitis B (CHB) patients and 120 samples from HCC patients.
Results: Serum miR-150 levels were significantly reduced in HCC patients, compared with healthy controls (P < 0.0001)
and CHB patients (P < 0.0001). Serum miR-150 levels were increased after surgical operation (P < 0.0001) and decreased
after tumor recurrence (P < 0.0001). Receiver operating characteristic curve (ROC) analyses suggested that serum miR-150
had significant diagnostic value for HBV-related HCC. It yielded an area under the curve (AUC) of ROC of 0.931 with
82.5 % sensitivity and 83.7 % specificity in discriminating HCC from healthy controls, and an AUC of ROC of 0.881 with
79.1 % sensitivity and 76.5 % specificity in discriminating HCC from CHB patients. Moreover, Kaplan-Meier curve analysis
revealed that HCC patients with lower serum miR-150 had a significantly shortened overall survival (P < 0.0001).
Univariate and Multivariable Cox regression analysis indicated that serum miR-150 level was an independent risk factor
for overall survival (P < 0.0001 and P = 0.015, respectively).
Conclusions: Serum miR-150 can serve as a non-invasive biomarker for the diagnosis and prognosis of HCC patients.
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Background
Hepatocellular carcinoma (HCC) is one of the most
common prevalent cancers, rated third in mortality
worldwide [1]. Although there are different viral and
non-viral causes of HCC, almost 80 % of HCC patients
are associated with hepatitis B virus (HBV) infection [2].
Currently, most HCC patients have a poor prognosis
with a relative low survive rate, which is due to their
diagnosis at advanced stages with limited therapeutic op-
tions. Alpha-fetoprotein (AFP) is widely used to detect
primary HCC but its sensitivity and specificity are
disputed [3]. Thus, it is prudent to search for more ef-
fective and reliable markers for diagnosis and prognosis
of primary HCC.
MicroRNAs (miRNAs), a class of small non-coding
RNAs, can regulate gene expression by binding to com-
plementary sequences in the 3′-untranslated region of
mRNAs [4–6]. Recently, miRNAs have been shown to
be involved in several physiological processes such as de-
velopment, apoptosis, proliferation, and differentiation,
and even play a critical role in carcinogenesis [7–9]. In
many cancers, aberrant expressions of tissue-miRNAs
may lead to poor prognosis, suggesting that they can func-
tion as oncogenes or tumor suppressor genes [10, 11].
Apart from their tissue-specific origin and expression,
miRNAs are also shown to be stable and detectable in
many body fluids including serum and plasma [12]. In-
creasing evidence has shown that circulating miRNAs
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have potential as non-invasive biomarker for HCC. For
example, Xie et al. found that serum miR-101 levels
were significantly down-regulated in the HBV-HCC
patients and could differentiate HBV-HCC form HBV-
associated liver cirrhosis [2]. Notably, altered serum/
plasma miRNAs levels are also associated with the
development of HCC [13].
Our group previously reported that over-expression of
miR-150 contributed to the suppression of activated
hepatic stallate cells (HSCs) in liver fibrosis, resulting in
the reduction of cell proliferation [14]. Interestingly,
Chang et al. found that Myc levels could be affected by
miR-150 in Myc-mediated tumorigenesis [15]. Zhang et
al. further demonstrated that miR-150 could inhibit
CD133-positive liver cancer stem cells by targeting c-
Myb [16]. Combined these, miR-150 might function as a
tumour suppressor in HCC. In addition, a recent study
showed that miR-150 is a factor of survival in non-small
cell lung cancer and associated with poor prognosis [17].
miR-150 also predicts a favorable prognosis in patients
with epithelial ovarian cancer, and inhibits cell invasion
and metastasis by suppressing transcriptional repressor
ZEB1 [18]. In this study, we evaluated whether serum
miR-150 could serve as a new biomarker for the diagno-
sis and prognosis of HBV-related HCC patients.
Methods
Study subjects
Serum samples were obtained from patients attending
the First Affiliated Hospital of Wenzhou Medical Uni-
versity from 2007 to 2011 (Table 1). This study popula-
tion consisted of 120 HBV-HCC patients, 110 chronic
hepatitis B (CHB) patients and 120 healthy controls
(with normal liver biochemistry, no history of liver dis-
ease or alcohol abuse and no viral hepatitis). For CHB
patients, blood samples were taken at the time when the
disease was active. The diagnosis of HCC was based on
histopathological assessment [19]. For HCC patients, the
pre-operative blood samples were taken at the time of
initial consultation. No patients underwent surgery or
received chemotherapy or radiotherapy before blood
sampling. In this study, HCC patients only underwent
surgery and no transplant cases included. Liver resection
was performed according to guidelines on the diagnosis
and treatment of primary liver cancer in China [20] and
the clinical experience of surgeons. In particular, the fol-
lowing requirements should be met for HCC patients
with multi-nodular disease or larger nodules: a) Basic
conditions: a patient’s general conditions should allow
him/her to tolerate surgery; the liver lesions are resect-
able; and the reserved liver function can serve in com-
pensation. Specifically, a patient in generally good
condition should have: no major disorders of the heart,
lung, kidney and other vital organs; normal liver
function, or with only mild damage (Child-Pugh class A),
or once Class B liver function that has recovered to Class
A after short-term routine therapy; hepatic functional re-
serve basically within the normal range; and no unresect-
able, extrahepatic metastatic lesions; b) Single liver with
smooth surface and clearly defined boundaries or pseudo-
capsule, <30 % liver tissue damaged by tumor, or damaged
tissue >30 % but with significantly compensatory enlarge-
ment of the contralateral lobes that exceed 50 % or more
of the standard liver volume; c) Multiple tumors with less
than five nodules that are confined to a single segment or
lobe of the liver. The post-operative blood samples were
collected a month after surgery and the relapsed blood
samples were collected at the diagnosis of tumor recur-
rence. Only 25 cases of blood samples could be collected
from the relapsed patients. Among these patients, 5 cases
with tumor metastasis are confirmed. Notably, none
underwent surgery or received chemotherapy or radio-
therapy before blood sampling. In addition, Child-Pugh
score [21] and the Barcelona Clinic Liver Cancer (BCLC)
Table 1 Patient information
Characteristic HCC (n = 120) CHB (n = 110) Control (n = 120)
Gender
Male 75 67 65
Female 45 43 55
Age
Mean ± SD 58 ± 10.4 55 ± 11.2 50 ± 9.5
AFP value
Mean ± SD 293.7 ± 705.5 18.8 ± 16.5 3.1 ± 1.2
HBsAg status
HBsAg+ 120 110 0
















HCC hepatocellular carcinoma; CHB chronic hepatitis B
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stage [22] were assessed by results of clinical examination,
imaging (dynamic computer tomography, magnetic reson-
ance imaging or abdominal ultrasound examination) and
laboratory parameters. The follow-up period is used for
calculating HCC patients’ survival rate. The follow-up
period was defined as the time from the date of surgery to
the date of patient mortality or the last follow-up point.
Follow up was completed on January 1, 2013. All HCC pa-
tients were monitored after surgery; diagnosis of recur-
rence was confirmed by ultrasound, enhanced CT scan,
MRI, and AFP levels. This project was approved by the
Ethics Committee of the First Affiliated Hospital of Wen-
zhou Medical University. Informed consent was obtained
from all participants for the use of their blood samples in
this study.
Samples processing and RNA extraction
The blood samples from all subjects were centrifuged at
3400 g for 7 min at room temperature, and the superna-
tants were transferred into Eppendorf tubes followed by
further centrifugation at 12000 g for 10 min at 4 °C.
Then the supernatants were stored at -80 °C pending
RNA extraction. All blood samples were processed
within 4 h after they were obtained. Total RNA contain-
ing small RNA was extracted from 500 μl of serum using
a miRNeasy Mini Kit (Qiagen, Carlsbad, California,
USA) according to the manufacturer’s instruction for li-
quid samples. DNase treatment (Qiagen, Carlsbad, Cali-
fornia, USA) was carried out to remove any containing
DNA. The final elution volume was 20 μl. All serum
RNA preparations were quantified by NanoDrop 1000
(Nanodrop, Wilmingtion, Delaware, USA).
microRNA quantification by real-time quantitative RT-PCR
Serum miR-150 level was quantified in triplicate by
qRT-PCR using TaqMan MicroRNA Assay Kits (Applied
Biosystems, Foster City, CA). The reverse transcription
reaction was performed in a 20 μl reaction volume using
specific primer for miR-150 contained in the TaqMan
MicroRNA Reverse Transcription kit (Applied Biosys-
tems, Foster City, CA). For synthesis of cDNA, the reac-
tion mixtures were sequentially incubated at 16 °C for
30 min, 42 °C for 30 min, and 85 °C for 5 min. Accord-
ing to the standard TaqMan MicroRNA assay protocol,
real-time PCR was performed in ABI 7500 Real-Time
PCR system (Applied Biosystems, Foster City, CA) with
the following cycle: 95 °C for 10 min, followed by 40 cy-
cles of 95 °C for 15 s and 60 °C for 60 s. Each PCR mix-
ture (20 μl) included the reverse transcription products,
TaqMan 2X Universal PCR Master Mix without UNG
Amperase, miRNA-specific TaqMan probes, and primers
supplied by Applied Biosystems. The cyclethreshold (Ct)
values were calculated with the SDS 2.0.1 software
(Applied Biosystems, Foster City, CA). The formula 2
−⊿Ct was used to calculate the miRNA levels in serum,
where ⊿Ct = mean (Ct of internal references) − Ct of
target miRNA. The relative expression levels of miR-
150 were calculated and normalized to miR-16 (Applied
Biosystems, Foster City, CA) using the comparative⊿Ct
method and the equation 2 −⊿Ct, as described previ-
ously [23].
Statistical analysis
ANOVA and χ2 test were used to compare demographic
characterization of study population. The significance of
serum miR-150 levels was determined by Mann–Whitney
U test. All tests were two-sided test and P < 0.05 was con-
sidered as statistically significant. Receiver operating char-
acteristic (ROC) curves were generated to classify patients
in different groups, as well as for the evaluation of the
diagnostic potential of serum miR-150 via calculation of
the area under the ROC curve (AUC), sensitivity and spe-
cificity according to standard formulas. Survival curves
were plotted using the Kaplan–Meier method and ana-
lyzed using the log-rank test. Univariate and multivariate
analyses of HCC prognostic factors were performed using
the Cox proportional hazards model. Statistical analyses
were performed with SPSS 13.0 (IBM, Armonk, NY).
Results
Patient population
Demographic and clinical characterizations of study
population are summarized in Table 1. A total of 350
participants including 120 HCC patients, 110 CHB pa-
tients and 120 healthy controls were recruited into this
study. There were no significant differences of age be-
tween patients with HCC patients, CHB patients and
healthy controls (P = 0.562, ANOVA). The sex distribu-
tion in the HCC group was 75:45, in CHB group was
67:43 and in control group was 65:55 (P = 0.381, χ2 test).
Expression profile of serum miR-150
Using qRT-PCR analysis, serum miR-150 expression
levels were measured in HCC patients, CHB patients
and healthy controls. Serum miR-150 levels were signifi-
cantly reduced in CHB patients group compared with
healthy control (P < 0.0001) (Fig. 1a). In addition, serum
miR-150 levels were significantly down-regulated in
HCC patients compared with the CHB patients (P <
0.0001) and healthy controls (P < 0.0001) (Fig. 1a). Not-
ably, the reduced serum miR-150 levels were restored
after surgical operation. Serum miR-150 levels were sig-
nificantly up-regulated in post-operative group com-
pared with pre-operative group (P < 0.0001) (Fig. 1b). To
further verify whether serum miR-150 level is associated
with HCC progression, serum miR-150 levels were ana-
lyzed by qRT-PCR in 25 paired post-operative and re-
lapsed serum samples. We found that miR-150 levels
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were significantly down-regulated in the relapsed sam-
ples compared with the post-operative samples (P <
0.0001) (Fig. 1c).
The diagnostic value of serum miR-150 for HCC
To confirm whether serum miR-150 level could be
served as a potential diagnostic marker for HCC, ROC
curve analysis was performed. Our results suggested that
serum miR-150 levels differentiated HCC patients from
healthy controls, with an AUC of ROC curve of 0.931
[95 % confidence interval (CI), 0.900 to 0.962] (Fig. 2a).
At the cutoff value of 0.720, the sensitivity and the speci-
ficity were 82.5 % and 83.7 %, respectively. Next, we
examined whether serum miR-150 levels could differen-
tiate HCC patients from CHB patients. The results indi-
cated that serum miR-150 levels differentiated HCC
patients from CHB patients, with an AUC of ROC curve
of 0.881 (95 % CI 0.837 to 0.926) (Fig. 2b). At the cutoff
value of 0.650, the sensitivity and the specificity were
79.1 % and 76.5 %, respectively. The potential diagnostic
Fig. 1 Serum miR-150 levels in healthy controls (n = 120), CHB patients (n = 110), HCC patients including pre-operative and post-operative
(n = 120), and relapsed patients (n = 25). a Comparison of miR-150 levels among the healthy control, CHB group, and HCC group (pre-operative).
b Comparison of miR-150 levels between pre-operative group and post-operative group. c Comparison of miR-150 levels between paired
post-operative and relapsed serums. The lines represent the range and median of relative miR-150 expression
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value of miR-150 for differentiating CHB patients with
healthy control was additionally evaluated. However,
ROC curve analyses showed that the AUC of serum
miR-150 level for discriminating CHB patients from
healthy controls was only 0.726 (95 % CI 0.660 to 0.793)
(Fig. 2c). At the cut-off value of 1.01, the sensitivity was
71.8 %, and the specificity was 65.0 %.
Serum miR-150 level, clinical characteristics, liver function
and survival in HCC patients
According to miR-150 median value (0.520), we divided
the pre-operative serum samples into low expression
and high expression groups in combination with the
clinicopathological data. The association between miR-
150 expression and clinical parameters was analyzed
(Table 2). We found that serum miR-150 levels were sig-
nificantly associated with TNM and BCLC stages (P <
0.0001) (Fig. 3), while there was no significant associ-
ation of miR-150 with clinical features such as gender,
age, AFP levels, tumor diameter and differentiation (P >
0.05). Furthermore, the association between miR-150 ex-
pression and prognosis was analyzed using Kaplan-
Meier analysis and log-rank test. The results suggested
that HCC patients with high expression of serum miR-
150 had a higher survival rate than those with low miR-
150 expression (median overall survival, 40.7 months vs
28.3 months, P < 0.0001) (Fig. 4). Univariate and multi-
variate Cox regression models were used to confirm the
variables of potential prognostic significance in all HCC
patients (Table 3). The result of univariate Cox regres-
sion analysis indicated that the reduced levels of serum
miR-150 were significantly correlated with overall sur-
vival [relative risk (RR), 0.329; P < 0.0001]. The multi-
variate Cox regression analysis demonstrated that
serum miR-150 level was an independent prognostic
factor for overall survival [RR, 0.446; P = 0.015]. As
confirmed by multivariate Cox regression analysis,
BCLC and TNM stages were also independent prognos-
tic factor for overall survival [RR, 2.631; P = 0.006 and
RR, 2.180; P = 0.020, respectively]. Moreover, to investi-
gate whether miR-150 level is related to liver function,
Fig. 2 ROC curve analysis of serum miR-150 for discriminating; (a) HCC patients from healthy controls, (b) HCC patients from CHB patients,
(c) CHB patients from healthy controls
Table 2 Correlation of serum miR-150 with clinicopathological






Male 75 39 36 0.866a
Female 45 21 24
Age (years)
≥60 64 32 32 0.315a
<60 56 28 28
AFP (ng/ml)
≥20 88 48 40 0.281a
<20 32 12 20
Tumor diameter (cm)
≥5 42 26 16 0.174a
<5 78 34 44
Differentiation
Poor 59 27 32 0.546a
Moderate +Well 61 33 28
BCLC stage
A 70 20 50 <0.0001a,b
B 50 40 10
TNM stages
I + II 73 22 51 <0.0001a,b
III 47 38 9
aMann-Whitney U test; bP < 0.05
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Fig. 3 Serum miR-150 levels in HCC patients with different TNM stages or BCLC stages. a The levels of miR-150 in TNM stages. I + II represented
TNM I and TNM II stages, and III represented TNM III stage. b The levels of miR-150 in BCLC stages
Fig. 4 Kaplan–Meier survival curves for HCC patients with low or high expression of serum miR-150
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we assessed Child-Pugh scores in CHB and HCC pa-
tients. It was found that miR-150 levels in CHB patients
with Child-Pugh A stage were higher than that of Child-
Pugh B stage (P < 0.0001) (Fig. 5). Likewise, higher miR-
150 levels were found in HCC patients with Child-Pugh
A stage compared with patients with Child-Pugh B
stage (P < 0.0001) (Fig. 5).
Discussion
HCC is the leading cause of cancer mortality in many
countries due to its high mortality rate [24]. Screening
for HCC allows early-stage diagnosis of the malignancy
and potentially reduces mortality of the disease. Current
diagnosis of HCC is based on imaging technology, serum
AFP levels, and histology [25]. These diagnostic tools
have variable effectiveness for early diagnosis of HCC;
cross-sectional imaging typically detects only tumors
greater than 1 cm in diameter, and serologic studies
also lack sensitivity and specificity in patients with
small tumors [26]. Based on these, investigators are
attempting to search for more effective serum bio-
marker in HCC patients.
In the last decades, numerous studies have shown that
aberrant miRNAs expression is associated with the de-
velopment and progression of various types of human
cancer, which indicates that miRNAs can be reliable bio-
markers for cancers [27–29]. Tissue-specific miRNAs
cannot be used on a wide scale because the procedure is
Table 3 Univariate and multivariate analysis for the prognostic significance of clinicopathological characteristics and serum miR-150
levels in HCC
Parameter Univariate analysis Multivariate analysisa
HR (95 % CI)b P-value HR (95 % CI)b P-value
Genderc 0.638 (0.358–1.136) 0.127
Agec 0.892 (0.520–1.528) 0.677
AFPc 1.693 (0.903–3.173) 0.095
Tumor diameterc 1.567 (0.909–2.703) 0.106
Differentiationc 1.560 (0.908–2.679) 0.107
BCLC stagesc 3.284 (1.830–5.540) <0.001d 2.631 (1.309–5.286) 0.006d
TNM stagesc 3.133 (1.803–5.444) <0.001d 2.180 (1.129–4.210) 0.020d
miR-150 0.329 (0.189–0.571) <0.001d 0.446 (0.233–0.854) 0.015d
aBackward Wald test used for variables screened, P = 0.05 was chosen as a criteria for significance; bCI, 95 % confidence interval; cgender, male vs. female;
age, ≥60 vs. <60 years; AFP, ≥20 vs. <20 ng/ml; tumor diameter, ≥5 vs. <5 cm; differentiation, poor vs. moderate and well; BCLC stage, B vs. A; TNM stage,
III vs. I and II; dP < 0.05
Fig. 5 Serum miR-150 levels in patients with different Child-Pugh stages. a The levels of miR-150 in CHB patients with different Child-Pugh stages.
b The levels of miR-150 in HCC patients with different Child-Pugh stages
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invasive; however, use of serum miRNAs is noninvasive
and thus more practical. Notably, serum miRNAs are re-
markably stable and expression patterns seem to be tis-
sue-specific, which makes it a good candidate for
noninvasive cancer testing [26]. The serum miRNAs were
firstly detected in the patients with diffuse large B cell
lymphoma, and subsequent studies have continually re-
ported the presence of miRNAs in circulation system and
body fluid, and revealed that miRNAs are potential diag-
nostic biomarkers and prognostic factors in cancers [12,
24, 30–32]. More recently, it was reported that plasma
miR-155, miR-197, and miR-182 could be potential nonin-
vasive biomarkers for early detection of lung cancer [32].
Li et al. identified miR-18a as a potential marker for hepa-
titis B virus-related HCC Screening [24]. Huang et al.
found that plasma miR-29a and miR-92a have signifi-
cant diagnostic value in advanced neoplasia [33]. These
reports prompted us to reveal more useful circulating
miRNA markers for different types of cancer with a
clinically satisfactory degree of sensitivity and
specificity.
In the present study, it was found that serum miR-150
levels were significantly reduced in patients with HBV-
related HCC when compared to those in healthy con-
trols, which was consistent with the previous studies
that indicated the reduction of miR-150 levels in HCC
tissue and cell lines [34, 35]. It yielded an AUC of 0.931,
with the sensitivity of 82.5 % and the specificity of
83.7 %. Chronic HBV infection is a known major etio-
logical factor for HCC development [36]. Therefore, we
further determine whether serum miR-150 could dis-
criminate HCC patients from CHB patients. Our results
showed that serum miR-150 could discriminate HCC
patients from CHB patients. It yielded an AUC of 0.881,
with the sensitivity of 79.1 % and the specificity of
76.5 %. In addition, serum miR-150 levels were mea-
sured in 120 paired pre-operative and post-operative
samples. We found that serum miR-150 levels were in-
creased in patients with HCC after surgical resection of
tumors. However, serum miR-150 levels were reduced
again after tumor recurrence in paired post-operative
and relapsed samples. These results suggested that miR-
150 acts as a tumor suppressor in the development of
HCC. The prediction of metastasis, recurrence, and
prognosis in patients with HCC after hepatic resection is
an important clinical issue that could determine the sur-
gical therapeutic regimen. In this study, we observed
that reduced miR-150 expression in HCC patients was
correlated negatively with advanced TNM stages, which
is highly correlated with the prognosis of HCC [37, 38].
These data showed that miR-150 could be used for the
prediction of the prognosis of HCC. Consistent with this
result, further study indicated that the down-regulated
miR-150 was associated with poor survival for patients with
HCC. The patients with low expression of serum miR-150
had lower survival rates. To our knowledge, it is the first re-
port to evaluate the prognosis value of serum miR-150 in
HCC. Moreover, the univariate and multivariate analysis
with Cox regression models revealed that serum miR-150
could potentially serve as an independent risk predictor for
the prognosis of HCC. Further study showed that miR-150
levels were reduced in CHB patients with Child-Pugh B
compared with patients with Child-Pugh A. The similar re-
sults are also shown in HCC patients, suggesting that miR-
150 level is associated with liver function.
The prediction of the prognosis and accurate patient
stratification are crucial to optimise personalised treat-
ment [39]. Besides TNM stages, BCLC staging system is
also an often used clinical classification for HCC patients
[22, 40]. Our results showed that lower miR-150 level
was found in patients with BCLC B stage compared with
patients with BCLC A stage, suggesting that miR-150 is
also associated with BCLC stage. Recently, it has been
demonstrated that the multikinase inhibitor sorafenib
has been validated to treat patients with advanced HCC
[41]. However, there is no advanced BCLC stage such as
BCLC C stage, due to the reason that none with metas-
tasis were included in this study. Our results showed
that miR-150 might be a tumor suppressor. Therefore, it
is speculated that miR-150 might be associated with
tumor metastasis. Whether miR-150 could be tested as a
biomarker for sorafenib efficacy should be studied in fu-
ture. In addition, there are other limitations in this
study. First, the sample size is relatively small and large
samples are needed to the further validations of this
marker. Second, where serum miRNAs come from or
how organs release miRNAs into the blood is still un-
known. Further studies are needed to prove it.
Conclusion
In conclusion, our findings suggested that serum miR-
150 might serve as a novel diagnostic and prognostic
marker for HCC. Our data serve as basis for further in-
vestigation, preferably in large prospective studies before
miR-150 can be used as a noninvasive screening tool for
HCC in routine clinical practice.
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